Solta Medical's Thermage FLX And TR-4 Return Pad Receive Registration Certifications In China
Portfolio Pulse from Benzinga Newsdesk
Bausch Health Companies Inc. and its subsidiary Solta Medical announced that China's National Medical Products Administration (NMPA) has approved Thermage FLX and the TR-4 Return Pad for use in China. This approval is a significant milestone for Solta Medical, expanding their business and showcasing the success of their R&D and Regulatory Teams. Thermage is a non-invasive skin treatment that has been performed over two million times globally. The approval allows Solta Medical to continue growing the Thermage brand in China, building on the success of Thermage CPT since 2015. The article also provides indications for the use of Thermage systems and important safety information for potential patients.
January 18, 2024 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bausch Health Companies Inc.'s subsidiary Solta Medical received NMPA approval for Thermage FLX and TR-4 Return Pad in China, which could lead to revenue growth in the Chinese medical aesthetics market.
The approval of Thermage FLX and TR-4 Return Pad in China is likely to have a positive impact on Bausch Health's short-term revenue prospects in the Chinese market. Given the size of the market and the previous success of Thermage CPT, this regulatory milestone could lead to increased sales and market penetration. The confidence in this analysis is high due to the direct mention of the approval and its significance for the company's growth strategy.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100